Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes

Journal of Experimental Medicine

Volumn 186, Issue 5, 1997, Pages 695-704

  Vierboom, Michel P M ^a   Nijman, Hans W ^a,b   Offringa, Rienk ^a   Van DerVoort, Ellen I H ^a   Van Hall, Thorbald ^a   Van Den Broek, Lambert ^a   Fleuren, Gert Jan ^a   Kenemans, Peter ^b   Kast, W Martin ^c   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P53;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CYTOTOXIC T LYMPHOCYTE; EMBRYO; ETIOLOGY; GENE MUTATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ANIMALS; CELL SURVIVAL; CLONE CELLS; EPITOPES; H-2 ANTIGENS; HISTOCYTOCHEMISTRY; IMMUNIZATION; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030769148     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.186.5.695     Document Type: Article

References (61)

1. Melief, C.J.M. 1992. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58:143-175.
2. Kast, W.M., R. Offringa, P.J. Peters, A.C. Voordouw, R.H. Meloen, A.J. Van der Eb, and C.J.M. Melief. 1989. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 59:603-614.
3. Greenberg, P.D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281-355.
4. Feltkamp, M.C.W., G.R. Vreugdenhil, M.P.M. Vierboom, E. Ras, S.H. Van der Burg, J. Ter Schegget, C.J.M. Melief, and W.M. Kast. 1995. CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25: 2638-2642.
5. Toes, R.E.M., R. Offringa, H.J.J. Blom, R.M.P. Brandt, A.J. Van der Eb, C.J.M. Melief, and W.M. Kast. 1995. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J. Immunol. 154:3396-3405.
6. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. de Plaen, B. van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash. DC). 254:1643-1647.
7. van den Eynde, B., B. Lethé, A. van Pel, E. de Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373-1384.
8. Mandelboim, O., G. Berke, M. Fridkin, M. Feldman, M. Eisenstein, and L. Eisenbach. 1994. CTL induction by a tumor-associated antigen octa-peptide derived from a murine lung carcinoma. Nature (Lond.). 369:67-71.
9. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. Van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-365.
10. Van Pel, A., P. Van der Bruggen, P.G. Coulie, V.G. Brichard, B. Lethé, B. Van den Eynde, C. Uyttenhove, J.-C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145:229-250.
11. Traversari, C., P. Van der Bruggen, I.F. Lüscher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plean, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453-1457.
12. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489-495.
13. Gaugler, B., B. van den Eynde, P. van der Bruggen, P. Romero, J.J. Gaforio, E. de Plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921-930.
14. De Plaen, E., K. Arden, C. Traversari, J.J. Gaforio, J.-P. Szikora, C. De Smet, F. Brasseur, P. Van der Bruggen, B. Lethé, C. Lurquin, et al. 1994. Structure, chromosomal localization, and expression of 12 genes of the mage family. Immunogenetics. 40:360-369.
15. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91:3515-3519.
16. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella, and S.A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
17. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:6458-6462.
18. Bakker, A.B.H., M.W.J. Schreurs, A.J. De Boer, Y. Kawakami, S.A. Rosenberg, G.J. Adema, and C.G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005-1009.
19. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 Mutation in human cancers. Science (Wash. DC). 253:49-53.
20. Denissenko, M.F., A. Pao, M.-S. Tang, and G.P. Pfeifer. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science (Wash. DC). 274:430-432.
21. Kuerbitz, S.J., B.S. Plunkett, W.V. Walsh, and M.B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:7491-7495.
22. Zambetti, G.P., and A.J. Levine. 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7:855-865.
23. Ludlow, J.W. 1993. Interactions between SV 40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J. 7:866-871.
24. Moran, E. 1993. Interaction of adenoviral proteins with Rb and p53. FASEB J. 7:880-885.
25. Momand, M., G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1237-1245.
26. Noguchi, Y., Y.-T. Chen, and L.J. Old. 1994. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA. 91:3171-3175.
27. Nijman, H.W., S.H. Van den Burg, M.P.M. Vierboom, J.G.A. Houbiers, W.M. Kast, and C.J.M. Melief. 1994. p53, a potential target for tumor-directed T cells. Immunol. Lett. 40:171-178.
28. Theobald, M., J. Biggs, D. Dittmer, A.J. Levine, and L.A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA. 92:11993-11997.
29. Houbiers, J.G.A., H.W. Nijman, S.H. Van den Burg, J.W. Drijfhout, P. Kenemans, C.J.H. Van de Velde, A. Brand, F. Momburg, W.M. Kast, and C.J.M. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072-2077.
30. Mayordomo, J.I., D.J. Loftus, H. Sakamoto, C.M. De Cesare, P.M. Appasamy, M.T. Lotze, W.J. Storkus, E. Appella, and A.B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357-1365.
31. Röpke, M., J. Hald, P. Guldenberg, J. Zeuthen, L. Norgaard, L. Fugger, A. Svejgaard, S. Van der Burg, H.W. Nijman, C.J.M. Melief, and M.H. Claesson. 1996. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA. 93:14704-14707.
32. Bertholet, S., R. Iggo, and G. Corradin. 1997. Cytotoxic T lymphocytes responses to wild-type and mutant mouse p53 peptides. Eur. J. Immunol. 27:798-801.
33. Lacabanne, V., M. Viguier, J.-G. Guillet, and J. Choppin. 1996. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur. J. Immunol. 26:2635-2639.
34. Dahl, A.M., P.C.L. Beverley, and H.J. Stauss. 1996. A synthetic peptide derived from the tumor-associated protein mdm-2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. 157:239-246.
35. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery, J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 developmentally normal but susceptible to spontaneous tumors. Nature (Lond.). 356:215-221.
36. Feltkamp, M.C.W., H.L. Smits, M.P.M. Vierboom, R.P. Minnaar, B.M. De Jongh, J.W. Drijfhout, J. Ter Schegget, C.J.M. Melief, and W.M. Kast. 1993. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242-2249.
37. Kaczmarek, L., M. Oren, and R. Baserga. 1986. Co-operation between the p53 protein tumor antigen and platelet-poor plasma in the induction of cellular DNA synthesis. Exp. Cell Res. 62:268-272.
38. Gorer, P.A. 1950. Studies in antibody response of mice to tumour inoculation. Br. J. Cancer. 4:372-381.
39. Sijts, E.J.A.M., F. Ossendorp, E.A.M. Mengedé, P.J. Van den Elsen, and C.J.M. Melief. 1994. An immunodominant MCF murine leukemia virus-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV type specificity of MCF-directed CTL. J. Immunol. 152:106-116.
40. Kast, W.M., L.P. De Waal, and C.J.M. Melief. 1984. Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells. J. Exp. Med. 160:1752-1760.
41. Feltkamp, M.C.W., M.P.M. Vierboom, R.E.M. Toes, F. Ossendorp, J. Ter Schegget, C.J.M. Melief, and W.M. Kast. 1995. Competition inhibition of cytotoxic T lymphocyte (CTL) lysis, a ore sensitive method to identify candidate CTL epitopes that antibody-detected MHC class I stabilization. Immunol. Lett. 47:1-8.
42. Ljunggren, H.-G., N. Stam, J.C. Öhlen, J.J. Neefjes, P. Höglund, M.-T. Meemels, J. Bastin, T.N.M. Schumacher, A. Townsend, K. Kärre, and H.L. Ploegh. 1990. Empty MHC class I molecules come out in the cold. Nature (Lond.). 346: 476-480.
43. Köhler, G., K. Fisher-Lindahl, and C. Heusser. 1981. Characterization of a monoconal anti H-2k antibody. In The Immune System. C. Steinberg and I. Lefkovits, editors. Karger, Basel. 2:202-208.
44. Neefjes, J.J., F. Momburg, and G.J. Hämmerling. 1993. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science (Wash. DC). 261:769-771.
45. Neisig, A., J. Roelse, E.J.A.M. Sijts, F. Ossendorp, M.C.W. Feltkamp, W.M. Kast, C.J.M. Melief, and J.J. Neefjes. 1995. Major differences in TAP-dependent translocation of MHC class I presentable peptides and the effect of flanking sequences. J. Immunol. 154:1273-1279.
46. Bouma, G.J., P.M.W. Van der Meer-Prins, F.P.M.J. Van Bree, J.J. Van Rood, and F.H.J. Claas. 1992. Determination of cytotoxic T-lymphocyte precursor frequencies using Europium labeling as a nonradioactive alternative to labeling with Chromium-51. Hum. Immunol. 35:85-92.
47. Seed, B., and A. Aruffo. 1987. Molecular cloning of the CD2 antigen, the T cell erythrocyte receptor, by a rapid immunoselection procedure. Proc. Natl. Acad. Sci. USA. 84:3365-3369.
48. Pennica, D., D.V. Goeddel, J.S. Hayflick, N. Reich, C.W. Anderson, and A.J. Levine. 1984. The amino acid sequence of murine p53 determined from a c-DNA clone. Virology. 134:477-482.
49. Falk, K., O. Rötschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.). 351:290-296.
50. Kast, W.M., and C.J.M. Melief. 1991. Fine peptide specificity of cytotoxic T lymphocytes against adenovirus-induced tumours and peptide-MHC binding. Int. J. Cancer. 6(Suppl.): 90-94.
51. Ohashi, P.S., S. Oehen, K. Buerki, H. Pircher, C.T. Ohashi, B. Odermatt, B. Malissen, R.M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 65:305-317.
52. Goverman, J.A., L. Woods, L.P. Larson, H. Weiner, L. Hood, and D.M. Zaller. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell. 72:551-560.
53. Hu, J., W. Kindsvogel, S. Busby, M.C. Bailey, Y. Shi, and P.D. Greenberg. 1993. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177:1681-1690.
54. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991-1045.
55. Olsson, T. 1995. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitus and multiple sclerosis. Immunol. Rev. 144:245-268.
56. Ridgway, W.M., H.L. Weiner, and C.G. Fathman. 1994. Regulation of autoimmune response. Curr. Opin. Immunol. 6: 946-955.
57. van Eden, W., S.M. Anderton, R. van der Zee, B.J. Prakken, C.P.M. Broeren, and M.H.M. Wauben. 1996. (Altered) Self peptides and the regulation of self reactivity in the peripheral T cell pool. Immunol. Rev. 149:55-73.
58. Roth, J., D. Dittmer, D. Rea, J. Tartaglia, E. Paoletti, and A.J. Levine. 1996. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against a lethal tumor cell challenge. Proc. Natl. Acad. Sci. USA. 93:4781-4786.
59. Milner, J. 1984. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature (Lond.). 310:143-145.
60. Visseren, M.J.W., A. Van Elsas, E.I.H. Van der Voort, M.E. Ressing, W.M. Kast, P.I. Schrier, and C.J.M. Melief. 1995. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154:3991-3998.
61. Kast, W.M., L. Roux, J. Curren, H.J.J. Blom, A.C. Voordouw, R.H. Meloen, D. Kolakofski, and C.J.M. Melief. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with an unbound peptide. Proc. Natl. Acad. Sci. USA. 88:2283-2287.